STOCKHOLM, 8 September, 2010 – Karo Bio AB (publ) has been notified that its partner Merck, based in Whitehouse Station, N. J., and known as MSD outside the United States and Canada, has decided to discontinue the development of MK-6913 for the treatment of hot flashes.

STOCKHOLM, Sweden, August 27, 2010. Karo Bio held a well attended seminar on Thursday. Professors Steven E. Nissen and Paul J. P. Kastelein together withDr Jens Kristensen, Karo Bio’s Chief Medical Officer, presented and discussed the rationale in the selected development route for eprotirome and the medical need for more effective treatments of dyslipidemia in high-risk patients with...

STOCKHOLM, Sweden, August 26, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today presents its development plan for the phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH).

STOCKHOLM, August 11, 2010. The Swedish biotech company Karo Bio AB (publ) (Reuters: KARO. ST) today announced that the development plan for the upcoming phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH) will be presented on Thursday August 26, 2010. In connection to the presentation, Professors...

STOCKHOLM, July 7, 2010. The Swedish biotech company Karo Bio AB (publ) (Reuters: KARO. ST) today announced the decision to initially develop its leading lipid-lowering candidate drug eprotirome for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH).